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Abstract
Lymphoblastoid cell lines (LCLs) and fibroblasts provide conveniently derived non-neuronal samples in which to investigate
the aetiology of schizophrenia (SZ) using gene expression profiling. This assumes that heritable mechanisms associated with
risk of SZ have systemic effects and result in changes to gene expression in all tissues. The broad aim of this and other
similar studies is that comparison of the transcriptomes of non-neuronal tissues from SZ patients and healthy controls may
identify gene/pathway dysregulation underpinning the neurobiological defects associated with SZ. Using microarrays
consisting of 18,664 probes we compared gene expression profiles of LCLs from SZ cases and healthy controls. To identify
robust associations with SZ that were not patient or tissue specific, we also examined fibroblasts from an independent
series of SZ cases and controls using the same microarrays. In both tissue types ANOVA analysis returned approximately the
number of differentially expressed genes expected by chance. No genes were significantly differentially expressed in either
tissue when corrected for multiple testing. Even using relaxed parameters (p#0.05, without multiple testing correction)
there were still no differentially expressed genes that also displayed $2-fold change between the groups of SZ cases and
controls common to both LCLs and fibroblasts. We conclude that despite encouraging data from previous microarray
studies assessing non-neural tissues, the lack of a convergent set of differentially expressed genes associated with SZ using
fibroblasts and LCLs indicates the utility of non-neuronal tissues for detection of gene expression differences and/or
pathways associated with SZ remains to be demonstrated.
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Introduction
As with many complex clinical phenotypes, the identification of
heritable factors associated with schizophrenia (SZ) remains a
challenge [1]. Despite a lack of agreement in exact details of
polymorphisms associated with SZ between different populations,
there is optimism that data from gene association studies, together
with analyses of gene expression studies in post-mortem brain, can
provide convergent evidence of candidate biological pathways
associated with the phenotype. For example, Harrison and
Weinberger have noted that many of the candidate susceptibility
genes associated with SZ are associated with synaptic plasticity [2].
The goal is to identify the dysregulated neurobiological pathways
that are associated with the genetic, cellular and developmental
pathways that result in the manifestation of SZ. High-throughput
microarray gene expression profiling is an effective approach for
the identification of candidate genes and associated molecular
pathways implicated in a wide variety of biological processes or
disease states. To date there has been a lack of consistency with
respect to the individual genes identified in gene expression studies
based on comparison of post-mortem brain tissue from SZ cases
and healthy controls. However, there has been a degree of
concordance in some gene ontology categories/pathways pro-
posed to characterise SZ. These include: increased expression of
genes involved in pre-synaptic function [3–6]; down-regulation of
genes involved in energy production [7–9], and down-regulation
of myelination/oligodendrocyte related genes [10–13]. There are
several challenges in generating and replicating expression findings
in post-mortem brain: (i) choice of appropriate brain region for
investigation; (ii) the heterogeneity of cell types within brain tissue;
(iii) the reliance on relatively small samples; and (iv) the impact of
cause of death and/or post-death handling of tissue on gene
expression [14]. Thus, the use of post-mortem brain tissue,
compounded by a range of other factors that contribute to
between-study variation (e.g. age, race, gender, different micro-
array platforms and analysis methods), could underpin the relative
lack of gene/transcript-level consistency between expression
studies [15–18].
To overcome some of these problems several groups have
considered the use of samples other than post-mortem brain. For
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reported to show biological differences between individuals with
SZ and healthy controls. The biological pathways themselves (cell-
cell signalling, cellular proliferation and death, immune response)
have been previously suspected to be involved in the pathophys-
iology of SZ [23,24]. In one comparison study, the expression
profiles of different tissues from the central nervous system (CNS)
were shown to have the highest degree of similarity to expression
profiles from whole blood compared to any other tissue type [25].
Notably, of 45 genes previously implicated in the aetiology of SZ,
21 were expressed both in whole blood and the CNS. Recently,
non-brain cell sources have emerged as an alternative for
investigating gene expression differences in SZ, including:
peripheral blood leukocytes (PBLs) [26,27]; lymphoblastoid cell
lines (LCLs) [28,29]; and olfactory epithelium (OE) [30]. The
results, to date, have shown little overlap with gene array studies
based on post-mortem brain tissue. In one study comparing gene
expression in different tissues, Glatt et al [31] assessed expression
of prefrontal cortex (PFC) post-mortem brain and peripheral blood
cells from different cohorts of SZ patients and controls, in order to
identify genes with differential expression across populations and
tissue types. They applied rigorous statistical analyses to limit false
positives and found six genes that were differentially expressed in
both tissues - less than expected by chance. Only one of these
genes (SELENBP1) displayed the same direction of change, the
differential expression of which was confirmed in lymphocytes by
qRT-PCR and in brain via immunohistochemistry.
The use of these alternative tissues is relevant to psychiatric
disease researchers because blood-based tissues (lymphocytes) are
more readily obtained, thereby allowing larger case-control studies
with optimal matching on key variables (e.g. age, race, sex).
However, the underlying hypothesis of such studies is the existence
of subtle, disease-related effects in all tissues of the body, but which
only exert a detrimental/disease-causing effect in the brain. This
hypothesis warrants validation – while non-neuronal tissues are
clearly convenient alternatives to post-mortem brain, questions
remain as to how informative gene expression studies based on
these samples will be. For example, if disease-related effects impact
on tissues other than the brain, one would predict that gene
expression studies based on two different tissue types should
provide comparable patterns of dysregulation.
The aim of this study was to compare gene expression in two
different non-neural tissue sources (LCLs and fibroblasts) from
patients with SZ versus controls in order to detect a robust set of
common SZ-associated defects in both tissues.
Materials and Methods
Participants
Lymphocytes. Participants in this study were recruited as
part of the Brisbane Psychosis Study (BPS), a case-control study,
the full details of which are provided elsewhere [32]. Samples were
well matched for age and gender distribution and in total 8 SZ
samples and 7 control samples, recruited from the general
population of Brisbane, were used in this study (Table 1). All
subjects were assessed with a modified Schedule for Clinical
Assessment in Neuropsychiatry and each patient diagnosis/well
control status was confirmed with a computerised diagnostic
system (OPCRIT). The diagnosis of SZ was assigned according to
DSM-IIIR criteria [33]. All subjects included in this study
provided written, informed consent and the study was approved
by the Wolston Park Hospital Institutional Ethics Committee.
Fibroblasts. Patients and controls in this aspect of the study
were also recruited as part of a study examining OE cultures in
psychosis [30]. A total of 8 SZ samples and 7 control samples were
used in this study (Table 1).
Sample preparation
Lymphoblastoid cell lines. LCLs were established by
Epstein-Barr virus transformation of lymphocytes as described
[34]. For RNA, cell lines were all grown under tightly controlled
growth conditions in the same batch of RPMI 1640 medium with
10% FCS and antibiotics, to limit variation in RNA production
related to cell culturing effects. Total RNA was extracted when
cells were in log phase growth and had been cultured for
approximately the same number of passages (approx. 4–6). RNA
Table 1. Information on schizophrenia patient and control
samples.
Sample ID Sex Age Antipsychotic Medication
LCL Samples
SZ patients
S1L M 29 None
S2L M 21 Clozapine
S3L M 26 Clozapine
S4L M 20 Clozapine
S5L M 23 Clozapine
S6L M 24 Risperidone
S7L M 26 Clozapine
S8L M 22 Clozapine
Controls
C1L M 20 None
C2L M 26 None
C3L M 23 None
C4L M 21 None
C5L M 25 None
C6L M 27 None
C7L M 26 None
Fibroblast Samples
SZ patients
S1F F 46 Pericyazine
S2F M 23 Zuclopenthixol
S3F M 30 Olanzapine
S4F F 44 Clozapine
S5F M 32 Trifluoperazine
S6F M 50 Olanzapine
S7F M 38 Flupenthixol; Olanzapine
S8F F 44 Risperidone
Controls
C1F M 23 None
C2F M 41 None
C3F F 29 None
C4F M 45 None
C5F M 25 None
C6F M 53 None
C7F F 29 None
doi:10.1371/journal.pone.0002412.t001
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quality and to obtain concentration.
Fibroblasts. Skin biopsies (1 mm
2) were collected under local
anaesthesia from the upper arm using aseptic conditions and
immediately immersed in 2 ml Dulbecco’s Modified Eagles
Medium (DMEM). Primary cultures were established using the
DMEM growth medium, with the modification of 1%
benzylpenicillin/streptomycin sulphate. Biopsies were carefully
placed in Petri-dishes (60 mm
2) and covered with a coverslip to
prevent air-bubble formation. DMEM growth medium (600 ml)
was added and explants incubated under optimal growth
conditions (37uC, 5% CO2). Epithelial outgrowth was monitored
under a microscope at 24 hour intervals, and DMEM growth
medium was supplemented with 100 ml fresh medium after
24 hours initially, and subsequently every 48 hours. When
fibroblast outgrowth reached confluency in the Petri-dish, the
fibroblasts were redistributed into 25 cm
2 tissue culture flasks.
When these cells reached confluency, they were pelleted and
stored in liquid nitrogen
Fibroblast cultures were re-established by rapidly thawing the
sample at 37uC and transferred to a tissue culture flask. Cell
growth was monitored every 24 hours and RPMI 1640 growth
media replaced every 48 hours. When fibroblast outgrowth
reached confluency cells were split into larger tissue culture flasks
until enough cells were obtained for a RNA extraction (six flasks,
each approximately 2–4610
7 cells). RNA extraction was under-
taken using QIAGEN RNeasyH midi-columns (Qiagen, Clifton
Hill, Victoria) using the animal cell protocol as outlined in the
product manual. RNA from all samples was run on an Agilent
Bioanalyzer to assess quality and to determine concentration.
RNA labelling and microarray hybridisation
A common reference experimental design was used. Human
universal reference from Stratagene was used as the reference
RNA, and labelled with Cyanine 3 dye in all microarray
experiments. The experiments were performed on Human
Genome v.2.1 oligo arrays, available from the Gene Array Facility
at The Prostate Centre, Vancouver General Hospital (http://
prostatelab.org/arraycentre/index.html). Each array contained
18,664 unique cDNA elements. Total RNA was used to generate
fluorescently labelled cDNA by the indirect amino allyl dUTP
(AA-dUTP) method using the Superscript
TM III Reverse Tran-
scriptase System. This is a two-step method; in the first step amino
allyl dUTP, an amine-modified nucleotide, is incorporated during
reverse transcription. Subsequently, monofunctional forms of
Cyanine 3 (Cy3) and Cyanine 5 (Cy5) dyes are reacted with the
AA-dUTP labelled cDNA. The labelled cDNA was purified and
incubated on an array at 37uC for 14 hours. Following
hybridization, slides were washed and scanned using an Affyme-
trix/Genetic Microsystems 418 Array Scanner (Genetic Micro-
systems). Data capture was performed using the software
ImaGene
TM Version 5.1 (BioDiscovery, California, USA).
Data analysis and filtering
The pixel intensity data from ImaGene
TM were imported into
GeneSpring
TM 7.2 (Agilent Technologies, CA) and signal
intensities for each spot, sample and reference signals were
corrected for background, normalised for intensity (Lowess
residual), and a ratio generated. The data was centralized by
dividing each measurement by the 50th percentile of all
measurements in that sample, to control for chip-wide variations
in intensity. Quality control data filtering was then performed to
remove signals that were present in ,85% of samples (,13/15)
and with expression values below that of the background as
calculated by the cross-gene error model [35].
When using LCLs (virus-transformed B-lymphocytes), different
subclones of B-cells could be randomly (a) infected with EBV, and
(b) selected in culture. Consequently, all immunoglobulin and B-
cell-related genes were removed from analysis, because any
apparent differences in the expression of these genes are more
likely to be an artifact rather than due to the disease under
investigation [28,36]. Differential expression was determined by
one-way ANOVA-Welch’s approximate t-test. A p-value cut off
,0.05 was used for the mean difference between groups.
Additionally a 1.2-fold change filter was imposed on the genes
found to be differentially expressed in SZ LCLs in order to
compare our data directly with those of Vawter and colleagues
[29]. who also assessed gene expression in SZ versus control LCLs.
The GenBank Accession numbers were used to detect any
common probes/genes between the two LCL gene lists.
Results
Lymphoblastoid cell lines
After quality control filtering and removal of immune/B-cell
related probes, 8,500 transcripts remained. Differential expression
was determined using the Welch t-test, a p-value of ,0.05
returned 550 probes. Of these, 545 and 10 had fold-changes of
$1.2 and $2 respectively, between the means of the SZ and
control groups. When p-values were adjusted for multiple
comparisons, there were no genes that remained significantly
differentially expressed (Table 2).
Fibroblasts
Out of the 9,999 transcripts which remained after quality
control filtering, 434 transcripts were determined to be differen-
tially expressed (Welch t-test, p,0.05). Of these, 339 and 0 had
fold-changes of $1.2 and $2 respectively, between the means of
the SZ and control groups. Correction for multiple testing
returned no significantly differentially expressed genes (Table 2).












a 8500 9999 5442
Expected by Chance 0.05 425 500 -
Welch 0.05 550 434 15
Welch 0.05+B&H FDR
b 00 0
Welch 0.05+2f o l d 1 0 0 0
Welch 0.05+1.2 fold
c 545 339 2
Welch 0.05+1.2 fold Up 238 189 0
Welch 0.05+1.2 fold Down 307 150 2
aData were filtered to have signal above background in $13/15 samples
bB&H FDR - Benjamini and Hochberg False Discovery Rate multiple testing
correction
cThis statistical and fold-change cut-off was chosen so data could be compared
to Vawter et al [29]
doi:10.1371/journal.pone.0002412.t002
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There were 15 probes in common between the LCL and
fibroblast differentially expressed probe lists when no fold-change
cut-off was applied or direction of change considered. However,
when direction and 1.2 fold-change filtering were imposed, only 2
of these genes (ADSL [-1.50-fold in LCLs and -1.28-fold in
fibroblasts, in SZ relative to controls] and LOC441204 [-1.24-fold
in LCLs and -1.23-fold in fibroblasts, in SZ compared to controls])
displayed the same direction of dysregulation (Table 2). When only
the direction of change was considered, irrespective of the
magnitude of the change, 1 additional gene (FLJ14833) was
putatively differentially expressed in common between fibroblasts
(-1.18-fold in SZ) and LCLs (-1.43-fold in SZ) from SZ patients
compared with controls.
Overlap with previously published LCLs expression data
Of 28 differentially expressed genes detected by Vawter et al
[29], 27 were represented on the microarrays used in our study.
There was only one gene, encoding basic transcription factor 3
(BTF3; NM_001207), in common between the 545 statistically
significant genes (p,0.05) with a $1.2 fold-change detected in
LCLs is this study and the 27 genes reported by Vawter et al [29].
This number of genes in common is that expected by random
chance.
Discussion
In this study we could find no constitutive gene expression
differences of large effect between unrelated SZ cases and controls
in either LCLs or fibroblasts. When a multiple testing correction
was applied there were no significantly differentially expressed
genes between SZ and controls in either tissue type. Moreover, we
also failed to find a significant overlap between the list of
differentially expressed genes in our panel of LCLs and those
reported by Vawter et al [29]. in a similar analysis. Although our
study is of limited sample size, we would generally expect small
samples to contribute to a high type 1 error rate. However, this
was not observed; the number of differentially expressed gene in
the case-control comparison of both tissues was approximately that
expected by chance. It should be noted that the LCLs and
fibroblast cultures were from non-overlapping case-control studies.
This adds a randomization to the tissue group comparisons which
should act as a filter to identify the more robust changes due to the
disease by decreasing noise due to chance differences in heritable
gene expression levels between individuals. An alternative strategy
would be to conduct between-tissue expression studies based on
samples from the same individuals. But because SZ is a
heterogeneous group of disorders, either approach may make
any true system-wide dysregulation of transcription difficult to
detect, especially if the effect size is small. When testing 20,000
genes with a per-gene alpha value of 0.05 the number of samples
needed to detect differentially expressed genes by t-tests with a fold
change of 1.2 is 112, whereas only eight samples are needed to
statistically have the power to detect a 2-fold difference (http://
bioinformatics.mdanderson.org/MicroarraySampleSize/Microar-
raySampleSize.aspx). By comparison, the LCL and fibroblast data
sets used in the current study each had the power to detect a SZ-
related expression difference of 1.65-fold. It is entirely feasible that
any expression differences related to the aetiology of SZ would be
of small effect, and that when testing unrelated individuals, it could
be below the level of natural variation.
Moreover, gene expression analysis of case-control samples does
not take into account the notion of individual-specific thresholds
for disease causality. With this concept, the absolute level of
expression of a given gene required to trigger SZ might be
different between individuals, and would be ‘set’ by their
constitutive global gene expression profile. One approach to
overcome this potential limitation is the use of monozygotic twins
discordant for disease. This type of analysis provides a powerful
tool for reducing genetic variation between cases and controls,
while simultaneously enhancing the detection of epigenetic
differences emanating from in utero or post-natal environmental
exposures [37]. We, and others, have used this approach
successfully in the study of gene expression differences in bipolar
disorder [28,36] and autism [38]. Thus its application to SZ seems
warranted.
Although the two non-neuronal tissues we have tested here have
provided limited utility in identifying SZ-associated gene expres-
sion abnormalities, it is plausible that very large case-control
samples (to reduce individual variation/SZ heterogeneity) of LCLs
or fibroblasts may be suitable for validation (e.g. by qRT-PCR) of
a small number of genes identified via other means. Additionally,
there are other non-post-mortem brain tissue sources that may
prove fruitful. For example, olfactory epithelium, a tissue
analogous to the neuroepithelium of the neural tube from which
the brain develops in the embryo has yet to be fully assessed.
Cultures of this tissue have been used to detect differences between
disease and non-diseased states [39,40] and thus could provide a
more relevant alternative to tissues of non-neuronal origin, such as
fibroblasts and LCLs, for studying a range of neurological
disorders. We have reported the findings of one such study
comparing gene OE expression profiles between SZ cases and
controls [30]. Although it should be noted that this was an
exploratory study and the conclusions should be interpreted
cautiously due to the heterogeneous cell population from the nasal
biopsy and the small amount of material obtained, which did not
allow for any validation of gene expression differences. A better
alternative still may be to derive neural stem cell lines from the OE
and use these to analyze gene expression changes related to SZ
and other brain diseases.
The ability to use non-neuronal tissues to explore transcription
in neuropsychiatric disorders is of heuristic value, allowing the
recruitment of larger sample sizes. While some studies have
suggested that white blood cells may be an appropriate alternative
to neuronal tissue, based on comparable expression of many
relevant genes and pathways [25] the results of the current study
do not support the hypothesis. The lack of robust disease-related
gene expression differences in both fibroblasts or LCLs weakens
the case that these non-neuronal tissue sources are informative for
detecting the underlying causative genetic and epigenetic changes
responsible for SZ predisposition and development. However, the
relatively small sample sizes used here do not rule out the
possibility of consistent yet subtle changes in gene expression being
detected in case-control analyses of substantially larger cohorts.
Acknowledgments
The authors are grateful to the patients and controls for their participation
in this study and thank Dr Sandra Pavey for helpful discussions
Author Contributions
Conceived and designed the experiments: NH JM NM RM FF AM BM.
Performed the experiments: NM RM HS CC DM CP. Analyzed the data:
NH NM AM BM. Contributed reagents/materials/analysis tools: HS CC
DM. Wrote the paper: NH JM NM RM AM BM. Other: Recruit and
screen the patients: JM.
Schizophrenia Gene Expression
PLoS ONE | www.plosone.org 4 June 2008 | Volume 3 | Issue 6 | e2412References
1. Sullivan PF (2005) The genetics of schizophrenia. PLoS Medicine 2: e212.
2. Harrison PJ (1999) The neuropathology of schizophrenia. A critical review of the
data and their interpretation. Brain 122 ( Pt 4): 593–624.
3. Mirnics K, Middleton FA, Marquez A, Lewis DA, Levitt P (2000) Molecular
characterization of schizophrenia viewed by microarray analysis of gene
expression in prefrontal cortex. Neuron 28: 53–67.
4. Mirnics K, Middleton FA, Stanwood GD, Lewis DA, Levitt P (2001) Disease-
specific changes in regulator of G-protein signaling 4 (RGS4) expression in
schizophrenia. Molecular Psychiatry 6: 293–301.
5. Vawter MP, Barrett T, Cheadle C, Sokolov BP, Wood WH 3rd, et al. (2001)
Application of cDNA microarrays to examine gene expression differences in
schizophrenia. Brain Research Bulletin 55: 641–650.
6. Chung C, Tallerico T, Seeman P (2003) Schizophrenia hippocampus has
elevated expression of chondrex glycoprotein gene. Synapse 50: 29–34.
7. Middleton FA, Mirnics K, Pierri JN, Lewis DA, Levitt P (2002) Gene expression
profiling reveals alterations of specific metabolic pathways in schizophrenia.
Journal of Neuroscience 22: 2718–2729.
8. Altar CA, Jurata LW, Charles V, Lemire A, Liu P, et al. (2005) Deficient
hippocampal neuron expression of proteasome, ubiquitin, and mitochondrial
genes in multiple schizophrenia cohorts. Biological Psychiatry 58: 85–96.
9. Prabakaran S, Swatton JE, Ryan MM, Huffaker SJ, Huang JT, et al. (2004)
Mitochondrial dysfunction in schizophrenia: evidence for compromised brain
metabolism and oxidative stress. Molecular Psychiatry 9: 684–697, 643.
10. Hakak Y, Walker JR, Li C, Wong WH, Davis KL, et al. (2001) Genome-wide
expression analysis reveals dysregulation of myelination-related genes in chronic
schizophrenia. Proceedings of the National Academy of Sciences 98: 4746–4751.
11. Pongrac J, Middleton FA, Lewis DA, Levitt P, Mirnics K (2002) Gene expression
profiling with DNA microarrays: advancing our understanding of psychiatric
disorders. Neurochemical Research 27: 1049–1063.
12. Tkachev D, Mimmack ML, Ryan MM, Wayland M, Freeman T, et al. (2003)
Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. The Lancet
362: 798–805.
13. Aston C, Jiang L, Sokolov BP (2004) Microarray analysis of postmortem
temporal cortex from patients with schizophrenia. Journal of Neuroscience
Research 77: 858–866.
14. Marcotte ER, Srivastava LK, Quirion R (2003) cDNA microarray and
proteomic approaches in the study of brain diseases: focus on schizophrenia
and Alzheimer’s disease. Pharmacology & therapeutics 100: 63–74.
15. Cheung VG, Spielman RS (2002) The genetics of variation in gene expression.
Nature Genetics 32 Suppl: 522–525.
16. Eady JJ, Wortley GM, Wormstone YM, Hughes JC, Astley SB, et al. (2005)
Variation in gene expression profiles of peripheral blood mononuclear cells from
healthy volunteers. Physiol Genomics 22: 402–411.
17. Morley M, Molony CM, Weber TM, Devlin JL, Ewens KG, et al. (2004)
Genetic analysis of genome-wide variation in human gene expression. Nature
430: 743–747.
18. Whitney AR, Diehn M, Popper SJ, Alizadeh AA, Boldrick JC, et al. (2003)
Individuality and variation in gene expression patterns in human blood. Proc
Natl Acad Sci U S A 100: 1896–1901.
19. Sourlingas T, Issidorides M, Alevizos B, Kontaxakis V, Chrysanthou-Piterou M,
et al. (2003) Lymphocytes from bipolar and schizophrenic patients share
common biochemical markers related to histone synthesis and histone cell
membrane localization characteristic of an activated state. Psychiatry Research
118: 55–67.
20. Mahadik SP, Mukherjee S, Laev H, Reddy R, Schnur DB (1991) Abnormal
growth of skin fibroblasts from schizophrenic patients. Psychiatry Research 37:
309–320.
21. Mahadik SP, Mukherjee S (1996) Cultured skin fibroblasts as a cell model for
investigating schizophrenia. Journal of Psychiatric Research 30: 421–439.
22. Miyamae Y, Nakamura Y, Kashiwagi Y, Tanaka T, Kudo T, et al. (1998)
Altered adhesion efficiency and fibronectin content in fibroblasts from
schizophrenic patients. Psychiatry and Clinical Neurosciences 52: 345–352.
23. McGlashan TH, Hoffman RE (2000) Schizophrenia as a disorder of
developmentally reduced synaptic connectivity. Archives of General Psychiatry
57: 637–648.
24. Weinberger DR (1999) Schizophrenia: new phenes and new genes. Biological
Psychiatry 46: 3–7.
25. Sullivan PF, Fan C, Perou CM (2006) Evaluating the comparability of gene
expression in blood and brain. Am J Med Genet B Neuropsychiatr Genet 141:
261–268.
26. Middleton FA, Pato CN, Gentile KL, McGann L, Brown AM, et al. (2005) Gene
expression analysis of peripheral blood leukocytes from discordant sib-pairs with
schizophrenia and bipolar disorder reveals points of convergence between
genetic and functional genomic approaches. Am J Med Genet B Neuropsychiatr
Genet 136: 12–25.
27. Tsuang MT, Nossova N, Yager T, Tsuang MM, Guo SC, et al. (2005) Assessing
the validity of blood-based gene expression profiles for the classification of
schizophrenia and bipolar disorder: a preliminary report. Am J Med
Genet B Neuropsychiatr Genet 133: 1–5.
28. Kakiuchi C, Iwamoto K, Ishiwata M, Bundo M, Kasahara T, et al. (2003)
Impaired feedback regulation of XBP1 as a genetic risk factor for bipolar
disorder. Nature Genetics 35: 171–175.
29. Vawter MP, Ferran E, Galke B, Cooper K, Bunney WE, et al. (2004)
Microarray screening of lymphocyte gene expression differences in a multiplex
schizophrenia pedigree. Schizophrenia Research 67: 41–52.
30. McCurdy RD, Feron F, Perry C, Chant DC, McLean D, et al. (2006) Cell cycle
alterations in biopsied olfactory neuroepithelium in schizophrenia and bipolar I
disorder using cell culture and gene expression analyses. Schizophrenia Research
82: 163–173.
31. Glatt SJ, Everall IP, Kremen WS, Corbeil J, Sasik R, et al. (2005) Comparative
gene expression analysis of blood and brain provides concurrent validation of
SELENBP1 up-regulation in schizophrenia. Proc Natl Acad Sci U S A 102:
15533–15538.
32. McGrath J, El-Saadi O, Grim V, Cardy S, Chapple B, et al. (2002) Minor
physical anomalies and quantitative measures of the head and face in patients
with psychosis. Archives of General Psychiatry 59: 458–464.
33. Association AP (1994) Diagnostic and statistical manual of mental disorders,
fourth editition (DSM-IV). Washington, DC.: American Psychiatric Press, Inc.
34. Neitzel H (1986) A routine method for the establishment of permanent growing
lymphoblastoid cell lines. Human Genetics 73: 320–326.
35. Silicon-Genetics (2002) Cross-gene error model. http://wwwsilicongenetics-
com/Support/GeneSpring/GSnotes/analysis_guides/error_modelpdf..
36. Matigian N, Windus L, Smith H, Filippich C, Pantelis C, et al. (2007) Expression
profiling in monozygotic twins discordant for bipolar disorder reveals
dysregulation of the WNT signalling pathway. Molecular Psychiatry.
37. Petronis A (2001) Human morbid genetics revisited: relevance of epigenetics.
Trends in Genetics 17: 142–146.
38. Hu VW, Frank BC, Heine S, Lee NH, Quackenbush J (2006) Gene expression
profiling of lymphoblastoid cell lines from monozygotic twins discordant in
severity of autism reveals differential regulation of neurologically relevant genes.
BMC Genomics 7: 118.
39. Feron F, Perry C, Hirning MH, McGrath J, Mackay-Sim A (1999) Altered
adhesion, proliferation and death in neural cultures from adults with
schizophrenia. Schizophrenia Research 40: 211–218.
40. Feron F, Perry C, McGrath JJ, Mackay-Sim A (1998) New techniques for biopsy
and culture of human olfactory epithelial neurons. Archives of Otolaryngology-
Head & Neck Surgery 124: 861–866.
Schizophrenia Gene Expression
PLoS ONE | www.plosone.org 5 June 2008 | Volume 3 | Issue 6 | e2412